Omega Diagnostics Group PLC Exercise of Options and Total Voting Rights (2242A)
20 Gennaio 2020 - 08:00AM
UK Regulatory
TIDMODX
RNS Number : 2242A
Omega Diagnostics Group PLC
20 January 2020
20 January 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Exercise of Options and Total Voting Rights
Omega Diagnostics (AIM: ODX), the medical diagnostics company
focused on allergy, food intolerance and infectious disease,
announces that it has allotted 80,000 new ordinary shares of 4
pence each in the capital of the Company ("Ordinary Shares")
following the exercise of share options by an ex-employee.
Application has been made to the London Stock Exchange for the
80,000 new Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 23 January
2020.
After Admission, the total number of Ordinary Shares in issue
will be 150,387,010 and the total number of voting rights will
therefore be 150,387,010. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
The information contained within this announcement is deemed by
the Company to constitute inside information stipulated under the
Market Abuse Regulation (EU) No. 596/2014. The below notification
is made in accordance with the requirements of the EU Market Abuse
Regulation.
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030
Bill Rhodes, Interim Non-Executive www.omegadiagnostics.com
Chairman
Colin King, Chief Executive
Kieron Harbinson, Group Finance
Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Hannah Boros (Corporate
Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOESFDFMWESSEEF
(END) Dow Jones Newswires
January 20, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Omega Diagnostics (LSE:ODX)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Omega Diagnostics (LSE:ODX)
Storico
Da Mar 2023 a Mar 2024